ProCE Banner Activity

CME

A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis

Multimedia
Watch this on-demand webcast from an ASH satellite symposium on the use of current and emerging therapies for patients with myelofibrosis, including discussions on individualized treatment plans, treatment for relapsed/refractory disease, managing treatment-related toxicities, and clinical trials.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: December 20, 2022

Expiration: December 19, 2023

No longer available for credit.

Share

Faculty

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Abdulraheem Yacoub

Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

AbbVie Inc.

CTI BioPharma Corp

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with myelofibrosis, including hematologists/oncologists, advanced care practitioners, pharmacists, and nurses.

Learning Objectives

  • Develop individualized treatment plans for patients with MF based on risk stratification and burden of symptoms
  • Plan evidence-based therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy
  • Institute best practices for transitioning to a clinically appropriate second-line therapy after first line treatment failure
  • Integrate supportive care plans into practice designed to monitor and manage treatment-related toxicities from new or novel MF treatments
  • Identify patients with MF who are eligible for enrollment on a clinical trial

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD: researcher: Bristol-Myers Squibb, Constellation, CTI, Incyte, Kartos, Novartis, PharmaEssentia, Protagonist, Sierra, Telios.

Faculty Disclosure

Primary Author

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS: consultant/advisor/speaker: PharmaEssentia.

Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Abdulraheem Yacoub, MD: consultant/advisor/speaker: AbbVie, Acceleron, CTI, Gilead Sciences, Incyte, Novartis, Pfizer, PharmaEssentia, Servier.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 20, 2022, through December 19, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve knowledge, confidence, and competence of healthcare professionals treating patients with myelofibrosis by leveraging recent and emerging data that must be considered in treatment decisions.